ReviewReviews in cardiovascular medicine2025
Cardiac Amyloidosis in the Real World: Clinical Presentations, Disease Overlap, and Therapeutic Imperatives.
Review in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnostic Performance of Relative Apical Sparing Across Cardiac Diseases: A Multimodality Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac amyloidosis (CA) has emerged from the margins of cardiology to the forefront of research and practice on heart failure. Once regarded as rare and elusive, CA is now recognized as a significant cause of heart failure with preserved ejection fraction (HFpEF), arrhythmias, and valvular disease, especially in older patients. CA is characterized by extracellular deposition of misfolded protein fibrils, which infiltrate the myocardium and disrupt the structural and electrical integrity. Although CA can stem from multiple amyloid types, transthyretin amyloidosis (ATTR) and light-chain (AL) amyloidosis are the predominant subtypes with cardiac involvement, each carrying distinct implications for prognosis and therapy. This review explores CA as a clinical reality often obscured by more common cardiovascular syndromes. Moreover, this review focuses on the varied presentations of CA in real-world practice, how the condition overlaps with HFpEF, the subtle clues for CA amid common valvular disorders, and the complex rhythm manifestations of the condition. Particular attention is given to thromboembolic risk, microvascular dysfunction, and the evolving paradigm of preclinical or asymptomatic amyloidosis management. Furthermore, this review addresses contemporary challenges such as financial toxicity and the cost-effectiveness of screening, emphasizing the benefits of early detection and therapy. The paper also discusses risk stratification and staging, drawing from validated models to guide both prognosis and treatment decisions, and the role of histopathological characterization. Thus, this review underscores the importance of timely recognition and tailored intervention in transforming CA from a terminal diagnosis into a manageable chronic condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.